

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY GUATEMALA	2. DATE OF BIRTH Day Month Year PRIVACY	2a. AGE 39 Years	3. SEX Male	3a. WEIGHT Unk	4-6 REACTION ONSET Day Month Year 08 MAR 2025	8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)							
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)		Product	Serious	Listed	Reporter Causality	Company Causality	
Vómitos [Vomiting]		XIGDUO	No	Yes	Related	Related	
Adormecimiento en brazos y piernas [Hypoaesthesia]		XIGDUO	No	No	Related	Related	
Adormecimiento en lengua [Hypoaesthesia oral]		XIGDUO	No	No	Related	Related	
Diarrea muy fuerte [Diarrhoea]		XIGDUO	No	Yes	Related	Related	
(Continued on Additional Information Page)							

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) XIGDUO (DAPAGLIFLOZIN, METFORMIN) Tablet {Lot # Unknown}	20. DID REACTION ABATE AFTER STOPPING DRUG? <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
15. DAILY DOSE(S) #1) 5 milligram, qd	16. ROUTE(S) OF ADMINISTRATION #1) Oral use
17. INDICATION(S) FOR USE #1) Type 2 Diabetes (Type 2 diabetes mellitus)	21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) 08-MAR-2025 / 13-MAR-2025	19. THERAPY DURATION #1) 6 days

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Indication	Type II diabetes mellitus (Type 2 diabetes mellitus)
Unknown to Ongoing	Indication	Type 2 diabetes mellitus (Type 2 diabetes mellitus)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorgiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000		26. REMARKS World Wide #: GT-ASTRAZENECA-202505CAM003462GT Study ID: PSP-23269 Case References: GT-AstraZeneca-CH-00864232A
	24b. MFR CONTROL NO. 202505CAM003462GT	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 06-MAY-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	NAME AND ADDRESS WITHHELD.
DATE OF THIS REPORT 07-MAY-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

07-May-2025 22:23

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Case Description: A solicited report has been received from a consumer in Patient Support Program. The report concerns a male adult patient born in 1985 (age 39 years).

No medical history was reported.

No concomitant products were reported.

The patient started treatment with Xigduo (dapagliflozin, metformin) (batch number(s) Unknown) 5 milligram qd, Oral use, on 08-MAR-2025 for type 2 diabetes.

On 08-MAR-25, the patient experienced vómitos (preferred term: Vomiting), diarrea muy fuerte (preferred term: Diarrhoea), adormecimiento en lengua (preferred term: Hypoaesthesia oral) and adormecimiento en brazos y piernas (preferred term: Hypoaesthesia).
The last dose of XIGDUO prior to onset was taken on 13-MAR-25.

Treatment with Xigduo (dapagliflozin, metformin) was discontinued on 13-MAR-2025.

The patient recovered from the event(s) adormecimiento en brazos y piernas, adormecimiento en lengua and vómitos after 6 days on 14-MAR-2025. The patient recovered from the event(s) diarrea muy fuerte after 15 days on 23-MAR-2025.

The events were considered non-serious.

The reporter considered that there was a reasonable possibility of a causal relationship between Xigduo and the following event(s): adormecimiento en brazos y piernas, adormecimiento en lengua, diarrea muy fuerte and vómitos.
The company physician considered that there was a reasonable possibility of a causal relationship between Xigduo and the following event(s): adormeciiento en brazos y piernas, adormecimiento en lengua, diarrea muy fuerte and vómitos.

Laboratory values are available.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1		Blood potassium UNK		